Literature DB >> 14609103

Large B-cell lymphoma of the leg in a patient with multiple malignant tumours.

Nora Eros1, Zsuzsanna Karolyi, Anikó Kovács, András Matolcsy, Tibor Barna, Gábor Kelényi.   

Abstract

A patient who had primary gastric B-cell non-Hodgkin's lymphoma, invasive ductal breast cancer and a basocellular carcinoma of the forehead in her medical history was studied. Three years after polychemotherapy and irradiation of the breast cancer, a rapidly enlarging, ulcerated violaceous tumour developed on the patient's left leg. The tumour was identified by the histopathological, immunohistochemical and immunoglobulin gene rearrangement analyses as a cutaneous large B-cell lymphoma. No signs of extracutaneous involvement were detectable. Despite surgical excision, interferon-alpha2b treatment and chlorambucil + prednisone chemotherapy, a relapse occurred in the previously affected site, whereafter the patient received radiotherapy. She was lost to follow-up, and died approximately 14 months after the surgical intervention without autopsy. We discuss the clinical and histologic features and outcome of the large B-cell lymphoma of the leg, its coincidence with other diseases, and the uncommon occurrence of primary multiple malignant tumours.

Entities:  

Mesh:

Year:  2003        PMID: 14609103     DOI: 10.1080/00015550310010612

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

Review 1.  Multiple haematological malignancies in a patient with rheumatoid arthritis without exposure to disease modifying therapy.

Authors:  H Piper; D Mulherin; N Hardwick
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

Review 2.  Breast Cancer and Multiple Primary Malignant Tumors: Case Report and Review of the Literature.

Authors:  Alessandro De Luca; Federico Frusone; Massimo Vergine; Rosario Cocchiara; Giuseppe La Torre; Laura Ballesio; Massimo Monti; Maria Ida Amabile
Journal:  In Vivo       Date:  2019 Jul-Aug       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.